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ABSTRACT: The lungs are a site for the uptake, accumulation, and storage of
exogenous basic amines. The compound N-N-N’-trimethyl-N’-(2-hydroxy-3-methyl-
5-iodobenzyl)-1,3 propanediamine (HIPDM) is a basic amine that can be labelled
with radioactive iodine and detected by external counting. Intravenously injected
123I-HIPDM is extracted by the human lung, where it is retained in a slowly efflux-
able pool.
In the present study, we measured HIPDM lung kinetics and subcellular distri-
bution in rabbits given i.v. 125I-HIPDM. Rabbits were killed from 2 min to 5 h
after injection, and the radioactivity retained in their lungs was measured. Subcellular
lung fractions (nuclear, mitochondrial, lysosomal, microsomal, and postmicroso-
mal supernatant) were assayed for HIPDM radioactivity, protein content, and dis-
tribution of specific marker enzymes.
HIPDM lung clearance in rabbits was nearly identical to that of humans. Virtually
all the HIPDM radioactivity in lungs (98±1%) was associated with subcellular
membranous structures. The highest HIPDM specific radioactivity was found in
the mitochondrial fraction, and the subcellular distribution profile closely resem-
bled that of the mitochondrial marker enzyme succinate cytochrome c reductase.
No redistribution of HIPDM among subcellular compartments was observed over
a 5 h period after injection.
The data indicate that mitochondria act as reservoir for HIPDM in the lungs
and contribute to the pulmonary persistence of this compound. HIPDM can be
used to investigate the pulmonary uptake of basic amines in health and in lung
disease.
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The lungs are a site for uptake, accumulation, and stor-
age of a variety of exogenous chemicals, including drugs
in clinical use. The available data on the pharmacokin-
etic function of the lung can be summarized as follows:
1) the compounds which concentrate most extensively
in the lungs are amines with a pKa greater than 8, col-
lectively grouped under the term of basic amines [1, 2];
2) many of these molecules are amphiphilic in nature,
inasmuch as they contain a large hydrophobic group and
a side chain which is protonated at physiological pH [1,
2]; 3) in contrast to endogenous biogenic amines [3], a
carrier-mediated, energy-dependent transport system is
not involved in the pulmonary uptake of basic amines
[4–6]; 4) no appreciable in vivo lung metabolism has
been reported for most of the basic amines investigat-
ed so far [4, 6–12]; 5) basic amines with amphiphilic
character, e.g. imipramine [8, 13], methadone [9, 13],
chlorphentermine [13], propranolol [10], verapamil [11],
and amiodarone [14], are retained in the lungs in a slow-
ly effluxable pool. At present, there is no obvious expla-
nation for the observed persistence of these drugs in the
lungs.
The radioiodinated compound N-N-N'-trimethyl-N'-
(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine
(HIPDM) is an amphiphilic basic amine similar to pneu-
mophilic drugs [15]. Although HIPDM was introduced
as a radiopharmaceutical for brain perfusion imaging,
preliminary biodistribution studies have indicated that
the lungs, rather than the brain, are the main storage site
for HIPDM [15]. As assessed in isolated perfused rat
lungs, the pulmonary uptake of HIPDM is saturable, does
not require an active transport system, and is competi-
tively inhibited by other basic amines, such as imipramine,
chlorpromazine and propranolol [16]. No significant in
vivo metabolism of HIPDM has been detected in rat and
rabbit lungs [17, 18].
Unlike other basic amines, the pulmonary uptake of
HIPDM can be visualized by external detection [19, 20].
Intravenously injected 123I-HIPDM is quickly extracted
by the human lung, where it is distributed according to
regional blood flow [20]. The resulting lung scan is indis-
tinguishable from that obtained by conventional perfu-
sion radiotracers. Furthermore, it has been observed that
HIPDM is cleared from the human lung at a slow expo-
nential rate [20]. The pulmonary persistence of HIPDM
is increased in asymptomatic smokers and in patients
with acute respiratory distress syndrome (ARDS) as com-
pared to healthy nonsmokers [18, 20].
In the present study, HIPDM was used to investigate
the mechanisms responsible for the pulmonary persis-
tence of basic amines. The time course of HIPDM bio-
distribution was first evaluated in rabbits receiving i.v.
bolus injection of labelled HIPDM. In additional exper-
iments, the lung subcellular distribution profile of the
compound was assessed by cell fractionation techniques.
Methods
Radiolabelling
The radiolabelling of HIPDM was carried out accord-
ing to the method described by KUNG et al. [15]. Briefly,
2 mCi of carrier-free Na125I (Sorin Biomedica, Salug-
gia, Italy) were added to 0.25 mL of HIPDM solution
(4 mg·mL-1 in 0.14 N HCl) in a sealed glass vial, and
the reaction mixture was heated in a boiling water bath
for 60 min. Radiochemical incorporation was evaluated
by thin layer chromatography (Silica Gel 60-F; Merck,
Darmstadt, Germany) using chloroform-ethanol-saturated
ammonia (80:15:5 by volume) as solvent. The labelling
yield was usually greater than 95% and the specific
activity of the labelled compound was approximately
0.3 Ci·mmol-1. Free iodine was removed by eluting the
reaction mixture through anion exchange resin (Biorex
AG 1-X8; Bio-Rad, Richmond, CA, USA).
Biodistribution studies
Forty six adult New Zealand albino rabbits (Stefano
Morini Laboratories, Reggio Emilia, Italy) weighing 2–3
kg were used throughout the study. They were fed with
a standard rabbit chow. The protocol was approved by
the Institutional Animal Care Committee. The animals
were injected, through the marginal ear vein, with a 0.5
mL bolus of saline containing an average of 37±9 µg
(mean±SD) of labelled HIPDM. At preselected times,
ranging from 2 min to 5 h after HIPDM injection, the
animals were killed by an intravenous dose of sodium
pentobarbital (50 mg·kg-1) and their lungs, liver, kidneys,
brain and spleen were quickly removed, blotted dry, and
weighed. Samples of peripheral blood were also obtained.
The excised organs were then minced and homogenized
in saline using a Polytron PT10 homogenizer (Kine-
matica, Luzern, Switzerland). Weighed aliquots of the
homogenates and of the blood, along with suitably dilut-
ed aliquots of the injected dose, were counted in a gamma
scintillation spectrometer (Packard Instruments, Warren-
ville, IL, USA) at a counting efficiency of about 75%.
Radioactivity per organ was expressed as percentage of
the HIPDM injected dose. The fraction of the injected
dose in the blood was estimated by using reference val-
ues of rabbit total circulating blood volume, as report-
ed in the literature [21].
In three additional rabbits, HIPDM radioactivity was
measured in bronchoalveolar lavage. Rabbits were given
an i.v. bolus of 125I-HIPDM, and were killed by sodium
pentobarbital overdose at 2 min, 1 and 4 h after the ad-
ministration of the labelled compound. The trachea was
exposed and clamped shut. The lungs and the trachea
were then removed intact and were dissected free of
other tissues. A plastic tube was inserted into the trachea
and the lungs were gently inflated with air until any
sign of atelectasis had gone. Next, 60 mL of ice-cold
phosphate-buffered saline were slowly instilled into the
lungs via the endotracheal tube and were made to recir-
culate five more times [22]. The lungs were then turned
upside down and the lavage liquid was allowed to drain
into a tared tube. Recovery of the lavage liquid was
73±6% of the instillate. Cells present in the lavage efflu-
ent were sedimented by an integrated force of 5,000
g·min. The cellular sediment (>90% alveolar macro-
phages as determined by light microscopy examination)
was resuspended in saline for in vitro counting. The
supernatant of the retrieved lavage liquid was layered
on a 0.75 M sucrose cushion and was centrifuged at
4,800,000×g·min [22]. The white band (alveolar sur-
factant) overlaying the sucrose cushion was collected
and partitioned in 1 mL aliquots for in vitro counting.
The lungs were then dissected free of the trachea and
of major airways, minced, and homogenized in saline
as described previously. The whole lung homogenate
was assayed for HIPDM radioactivity. Counts in lung
homogenate, lavage cells, and alveolar surfactant were
expressed as percentage of the total HIPDM radioac-
tivity recovered.
Lung cell fractionation studies
Twenty two adult New Zealand albino rabbits were
used in these experiments. As for biodistribution stud-
ies, the rabbits received an i.v. bolus of labelled HIPDM
and were killed with a lethal injection of sodium pen-
tobarbital at various times (from 2 min to 5 h) after
HIPDM administration. The lungs were excised, dis-
sected free of major airways, weighed and minced. The
lung mince was homogenized in 10 vol of ice-cold medi-
um (0.25 M sucrose, 0.005 M Tris hydrochloride, 0.001
M MgCl2, pH 7.4 at 4°C) using a Polytron PT 10 homo-
genizer for 2×10 s at maximum speed. The resulting
slurry was strained through two layers of gauze and sub-
jected to differential centrifugation by a modification of
the method described by DE DUVE et al. [23]. Prior to
centrifugation, weighed aliquots of the homogenate and
of the filtrate were set aside for further determinations
as described below. All the subsequent manipulations
were conducted at 4°C in tared tubes. Undisrupted cells
and nuclei, henceforth referred to as nuclear fraction,
were sedimented by an integrated force of 20,000 g·min.
The supernatant, which contained the cytoplasmic extr-
act, was further fractionated and three particulate frac-
tions, mitochondrial, lysosomal and microsomal, were
successively sedimented by integrated forces of 88,000,
200,000 and 4,440,000 g·min, respectively. All four sed-
iments were washed once in cold medium (0.05 M Tris
hydrochloride, 0.01 M MgCl2, 0.075 M NaCl, pH 7.4
at 4°C) by resuspension and recentrifugation. The wash-
ings were then discarded and the wet weight of each
sediment was measured. Weighed samples of each sed-
iment and of the final supernatant were taken for mea-
suring the retained HIPDM radioactivity and the protein
content. The latter was measured by the BCA Protein
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Assay (Pierce Chemical Company, Rockford, IL, USA)
using bovine serum albumin as a standard. The same
determinations were carried out on the samples of the
homogenate and of the filtrate laid aside previously.
Additional aliquots of the subcellular fractions were
assayed for the following enzymatic activities: succin-
ate cytochrome c reductase (mitochondrial marker enz-
yme); arylsulphatase B (lysosomal marker enzyme); and
NADPH-cytochrome c reductase (microsomal marker en-
zyme). Succinate cytochrome c reductase was measured
as described by SOTTOCASA et al. [24]. Arylsulphatase B
was assayed by the spectrophotometric method of BAUM
et al. [25], as modified by HALL et al. [26]. NADPH-
cytochrome c reductase determination was carried out
by a modification of the method of SILER MASTERS et al.
[27].
Because the mitochondrial fraction of the mammalian
lung is contaminated by lamellar bodies originating from
alveolar type 2 pneumocytes [28], 10 additional lung cell
fractionation experiments were carried out in which lam-
ellar bodies were isolated from mitochondria in order
to measure the partitioning of 125I-HIPDM between these
two subcellular components. In these experiments, rab-
bits were killed by sodium pentobarbital overdose at 5
min and at 3 h after HIPDM i.v. injection. For the iso-
lation of lamellar bodies, the methods described by PAGE-
ROBERTS [29] and by HASSETT et al. [30] were used, with
some modification. Briefly, the crude mitochondrial sed-
iment, obtained as described previously, was resuspended
in 2 mL of 0.33 M sucrose in 0.01 M Tris hydrochlo-
ride, pH 7.4, at 4°C (0.33 M sucrose-Tris) and weighed.
A weighed aliquot of the crude mitochondrial suspen-
sion was set aside for measuring HIPDM radioactivity.
The residual suspension was layered on 5 mL of 0.80
M sucrose-Tris and centrifuged at 1,600,000×g·min. The
procedure was conducted at 4°C in tared tubes. After
centrifugation, there was a light amber-coloured mito-
chondrial sediment and a white band, containing lam-
ellar bodies, at the interface between 0.33 and 0.80 M
sucrose. The white band was gently removed, diluted
with 0.22 M sucrose-Tris to a final volume of 8 mL, and
centrifuged at 1,600,000 g·min to yield a tightly packed
white pellet. Weighed aliquots of the purified mito-
chondrial and lamellar body sediments were assayed for
HIPDM radioactivity.
In preliminary experiments, the two sediments were
characterized biochemically by measuring the phos-
pholipid:protein ratio. Lipids were extracted according
to FOLCH et al. [31], using a chloroform-methanol mix-
ture (2:1 by volume). Inorganic phosphorus in per-
chloric acid digests of the lipid extract was assayed
according to SHIN [32]. The phospholipid content was
then calculated by multiplying the lipid-phosphorus by
25 [33]. In the present experiments, the phospholi-
pid:protein ratios of the lamellar body and of the puri-
fied mitochondrial sediment were 4.77±0.42 and 0.36±
0.08, respectively. These values are in close agreement
with those reported by GIL and REISS [28] for the lam-
ellar body and mitochondrial fractions obtained from
rat lung homogenate.
Results
Biodistribution studies
Biodistribution data of HIPDM in rabbits are pres-
ented in table 1. Two minutes after HIPDM i.v. admin-
istration, approximately 90% of the injected dose was
recovered from the lungs. Radioactivity in the liver and
in the total circulating blood volume accounted for 2
and 4% of the injected dose, respectively. Negligible
amounts of radioactivity (<1% of the dose) were recov-
ered from the other organs. As a function of time, the
clearance of HIPDM from the lungs was biphasic, with
an initial faster wash-out followed by a more gradual
decline of radioactivity. In the liver and kidneys, the
radioactivity increased progressively and, by 5 h after
injection, averaged 12 and 5% of the injected dose,
respectively. Throughout the study, the blood radioac-
tivity declined to a constant value of about 1.5% of the
injected dose; brain and spleen activity did not exceed
1% of the dose.
Figure 1 shows the percentage of HIPDM injected
dose in the lungs, liver, brain, kidneys and spleen, nor-
malized to the corresponding organ weight. It appears
that, throughout the period of experimental observa-
tion, the concentration of HIPDM was highest in the
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Table 1.  –  Biodistribution of HIPDM in rabbits
HIPDM  % injected dose
Time Lungs Liver Kidneys Brain Spleen Blood*
min
2 90±7 2.1±0.4 0.8±0.5 0.5±0.1 0 3.9±2.6
15 50±12 5.2±1.2 4.0±0.8 0.9±0.3 0.1±0.0 2.7±0.0
30 52±11 6.2±1.2 4.2±1.2 0.7±0.3 0.3±0.2 1.8±0.5
45 39±11 8.3±3.5 4.5±1.6 0.7±0.3 0.3±0.2 1.8±0.4
60 31±5 7.1±0.8 5.3±0.9 0.8±0.1 0.3±0.2 1.6±0.0
90 22±2 11±2 5.6±0.5 1.0±0.3 0.5±0.1 1.7±0.2
120 23±7 13±3 6.9±1.3 1.0±0.1 0.4±0.2 1.8±0.4
150 21±6 13±3 6.1±0.6 1.0±0.1 0.5±0.1 1.4±0.2
180 21±7 13±2 4.9±1.1 1.0±0.2 0.5±0.3 1.6±0.2
240 17±5 15±4 4.5±1.1 0.8±0.1 0.3±0.1 1.5±0.4
300 13±4 12±1 4.9±2.2 0.7±0.2 0.4±0.1 1.4±0.3
Values are presented as mean±SD of four different experiments. *: % of HIPDM injected dose in total circulating blood volume.
HIPDM: N-N-N'-trimethyl-N'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3 propanediamine.
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Fig. 1.  –  Biodistribution of HIPDM in rabbits. Bars representt the
percentage of injected dose in the lung, liver, brain, kidney and spleen,
normalized to the corresponding organ weight. Values are presented
as mean±SD. For the sake of clarity, experimental data obtained at 15,
30, 45, 90 and 150 min are omitted.       : 2 min;       : 60 min;       :
120 min;      : 180 min;       : 240 min;       : 300 min. HIPDM: N-
N-N'-trimethyl-N'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3 propanedi-
amine.
lungs. Even at 5 h after injection, the radioactive con-
centration in the lungs was higher than that measured
in the liver, brain, kidneys and spleen, by a factor of
10, 20, 8 and 6, respectively.
The time course of HIPDM clearance from the lungs
was further characterized by applying nonlinear regres-
sion analysis to the experimental data. The efflux of
HIPDM from the lungs was adequately described by a
biexponential function (fig. 2). The half-times of the fas-
ter and of the slower exponential component were 18
min and 4.3 h, respectively (fig. 2). The mean times of
the two exponential components, computed from the cor-
responding decay constants (λ), were 26 min and 6.2 h,
respectively. The size of the slowly effluxable pool, esti-
mated by backward extrapolation of the slower expo-
nential component of HIPDM efflux, accounted for 30%
of the injected dose.
In the three rabbits in which we did bronchoalveolar
lavage (BAL), the radioactivity associated with lavage
cells and alveolar surfactant did not exceed 3 and 0.2%
of the total HIPDM activity recovered, respectively.
Indeed, at any time after HIPDM i.v. injection, most of
the radioactivity recovered (98±1%) was retained by the
lung tissue after BAL.
Lung cell fractionation studies
The subcellular distributions of HIPDM and of pro-
tein, obtained by averaging the data of 22 consecutive
experiments, are presented in table 2. HIPDM and pro-
tein in each subcellular fraction are expressed as a percen-
tage of their respective cumulative amounts recovered
from all the fractions. In these experiments, the cumu-
lative radioactivity recovered from the fractions aver-
aged 98±3% of the radioactivity measured in the filtrate
prior to centrifugation, thus indicating no significant loss
of tracer in the fractionation procedure.
Virtually all the radioactivity retained in the lungs at
any time was associated with subcellular membranous
structures, the nuclear and mitochondrial fractions con-
taining the bulk of the compound. Less than 2% of the
total radioactivity in the lungs was recovered from the
final supernatant. As a function of the time elapsed from
the administration of the compound, the percentage of
total radioactivity in each sediment did not appreciably
change, suggesting no redistribution of HIPDM in sub-
cellular compartments.
The relative specific radioactivity of HIPDM in the
subcellular fractions was calculated by dividing the per-
centage of total radioactivity in each fraction by the cor-
responding percentage of total protein [23]. The mean
values of HIPDM relative specific radioactivity in the
fractions are given in table 2. A more illustrative analy-
sis of the results is obtained by plotting the mean rela-
tive specific radioactivity of the fractions against their
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Fig. 2.   –   Efflux of HIPDM from the rabbit lung. The curve is obtained
by in vitro counting of lung homogenates from rabbits killed at vari-
ous times after 125I-HIPDM i.v. injection. Data are reported on a semi-
log scale as percentage of the injected dose. Values at each time are
the average±SD of four different experiments. The experimental curve
has been  resolved into two exponential components (dashed straight
lines). λ1 and λ2 are the slopes (decay constants) of the two expo-
nentials; C1 and C2 are the intercepts to the y-axis for the respective
exponentials. The solid line represents biexponential fitting of exper-
imental data. HIPDM efflux = C1e-λ1t + C2e-λ2t. For definitions see
legend to figure 1.
Table 2.  –  HIPDM and protein in subcellular fractions
of rabbit lung
Fraction HIPDM Protein HIPDM %/
% % protein %
Nuclear 55±4 37±7 1.6±0.3
Mitochondrial 31±2 5±1 6.5±1.2
Lysosomal 7.1±1.8 1.8±0.5 4.1±1.1
Microsomal 4.8±1.6 3.7±0.9 1.4±0.6
Supernatant 1.9±0.9 53±8 0.04±0.01
HIPDM and protein in each subcellular fraction are expressed
as the percentage of their respective cumulative amounts recov-
ered from all fractions. HIPDM %/protein %: HIPDM relative
specific radioactivity. Data are presented as mean±SD of 22
determinations carried out at preselected times from 2 to 300
min after HIPDM i.v. injection. For individual time points and
further definitions see legend to table 1.
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relative protein content (fig. 3). The area of each block
is, thus, proportional to the percentage of radioactivity
recovered in the corresponding fraction, and its height
to the relative HIPDM concentration. In figure 3, the
subcellular distribution profiles of marker enzymes for
mitochondria, lysosomes, and microsomes are reported
for comparison, using the same graphic display. The high-
est relative specific radioactivity of HIPDM was found
in the mitochondrial fraction. Indeed, the subcellular
distribution profile of HIPDM closely resembled that of
the mitochondrial marker enzyme, succinate cytochrome
c reductase, thus suggesting a predominant localization
of the compound in the mitochondria. Such preferential
distribution remained unchanged as a function of time
from the i.v. administration of the compound.
In 10 additional lung cells fractionation experiments,
the crude mitochondrial sediment was purified  from
lamellar body contamination. The cumulative HIPDM
radioactivity recovered from the purified mitochond-
rial and lamellar body fractions averaged 99±0.5% of
the radioactivity measured in the crude mitochondrial
sediment prior to density gradient centrifugation. After
removing lamellar bodies, the purified mitochondrial
sediment retained 82±1% of the HIPDM radioactivity
measured in the crude mitochondrial sediment.
Discussion
The results of the present study indicate that the radio-
iodinated basic amine, HIPDM, is extracted by the rab-
bit lung from which it is cleared at a slow biexponential
rate. As shown by previous experiments on the meta-
bolism of HIPDM, more than 90% of the radioactivity
recovered from the lungs of rats and rabbits is in the
form of unmetabolized compound [17, 18]. By contrast,
HIPDM is extensively metabolized in the liver [17, 18].
The above findings are consistent with the observation
that rat and rabbit lungs are devoid of diamine oxidase
activity [34]. Hence, the observed rate of clearance of
radioactivity from the rabbit lung mostly reflects the
behaviour of unmetabolized HIPDM. The pulmonary
clearance of HIPDM in rabbits is similar to that observed
in humans by external detection [20]. In fact, the mean
time of the slower exponential component of HIPDM
lung efflux in rabbits (6.2 h) approximates the value
computed in normal nonsmokers (6.7±0.6 h) [20]. The
amount of tracer cleared with the slower exponential
component accounts for approximately 30% of the in-
jected radioactivity. Thus, in the rabbit lung, a sizeable
fraction of HIPDM is retained in a slowly effluxable
pool. The formation of a slowly effluxable pool has been
described, in isolated-perfused lungs, for a variety of basic
amines [8–11, 14]. In these experiments, the size of the
slowly effluxable pool was similar to that observed for
HIPDM, ranging 30–55% of the drug accumulated by
the lungs [8, 9, 11, 14]. For imipramine, a pulmonary
persistent pool with a mean residence time in excess of
5 h has also been demonstrated in vivo in rabbits receiv-
ing i.v. bolus injection of the labelled compound [13].
Because only those basic amines with amphiphilic
character are retained by the lungs in a slowly efflux-
able pool, it has been speculated that such a persistent
pool could result from the interaction of these molecules
with lung phospholipids, namely with the alveolar sur-
factant [1, 2, 8, 13]. The present data do not support
this hypothesis, inasmuch as it was found that very little
HIPDM radioactivity was associated with alveolar sur-
factant obtained by BAL. At any time after i.v. injec-
tion, most of the HIPDM radioactivity recovered from
the lungs (98±1%) was associated with intracellular
particulate fractions (table 2). The subcellular distribu-
tion profile of HIPDM, derived from lung cell frac-
tionation studies, was consistent with a predominant
localization of the compound in the mitochondria (fig.
3). After removing the lamellar body contamination from
the crude mitochondrial fraction, most of the HIPDM
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radioactivity was still retained in the purified mito-
chondrial sediment. Thus, it appears that the mitochon-
dria are important sites for the accumulation of HIPDM
in the lungs.
The findings of the present study are in agreement
with those of YOSHIDA et al. [35], who evaluated the
subcellular distribution of the basic amines imipramine,
quinine, and metoclopramide in the rat lung. The accu-
mulation of these drugs was highest in the crude mito-
chondrial fraction and was correlated to the degree of
lipid solubility, imipramine (the most lipophilic com-
pound) exhibiting the highest relative accumulation in
mitochondria [35]. The subcellular distribution of basic
amines, described by YOSHIDA et al. [35], was measured
in isolated rat lungs after 60 min of perfusion. In the pre-
sent experiments, the subcellular distribution of HIPDM
was examined in rabbit lungs at various times after in
vivo i.v. injection of the labelled compound. It was
observed that the preferential distribution of HIPDM in
the mitochondrial fraction was constant over a period
of time ranging from 2 min to 5 h after the i.v. admin-
istration of the compound. Since, during this time HIPDM
is slowly cleared from the lungs at a biexponential rate
(fig. 2), the above finding suggests that the persistence
of HIPDM in the lungs is accounted for by the inter-
action of the compound with lung mitochondria.
The preferential distribution of basic amines in the
mitochondria may result from binding to specific phos-
pholipids, such as cardiolipin and phosphatidylethano-
lamine, known to be rich in mitochondrial membranes
[36]. However, the mitochondria have a distinctive prop-
erty over any other intracellular organelle, i.e. they
express a significant membrane potential with a nega-
tive charge inside [37]. Indeed, a proton gradient is est-
ablished across the inner mitochondrial membrane as a
result of active extrusion of protons driven by electron
transport chains [37, 38]. This gradient has a chemical
component (pH gradient) and an electric component
(membrane potential). The mitochondria of mammalian
cells express this electrochemical gradient mostly as
membrane potential of about -180 mV and, to a lesser
extent, as pH gradient of about 1 unit [37]. Lipophilic
compounds with a delocalized positive charge (e.g.
HIPDM) may, therefore, penetrate the hydrophobic core
of the inner mitochondrial membrane and attain an equi-
librium across the membrane as predicted by the Nernst
equation [37].
The in vivo results of this study support the concept
that the mitochondria act as reservoir for the basic am-
ine HIPDM in the lungs and, as such, contribute to the
persistence of this compound in the lung tissue. The obs-
ervation of an increased persistence of HIPDM in the
lungs of smokers [20] and of patients with acute respi-
ratory distress syndrome [18] may reflect some bio-
chemical alteration of mitochondrial membranes that
warrants further investigation. In this connection, it is
worth considering that an unusual retention of the mito-
chondria-specific, fluorescent probe rhodamine 123 has
been described in vitro in a variety of carcinoma cells
[39], which express a significantly higher mitochon-
drial membrane potential as compared to normal epithe-
lial cells. HIPDM or related compounds can be used to
further investigate the pulmonary uptake of basic amines
in health and in lung disease.
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